Generating tumor-specific cytotoxic T cells in vivo


At Immune Design, we are developing cutting-edge product strategies for effective cancer immunotherapies that we believe take into consideration the limitations of other approaches, as well as leveraging different mechanisms of action to address the risk of reliance on a single approach.

Our product candidates are designed for superior generation and expansion of cytotoxic T lymphocytes to kill tumors, and intended to combine with other mechanisms of action across the oncology landscape, such as checkpoint inhibitors or engineered T cells, to increase the benefit to patients and potentially place Immune Design at a central place in the treatment paradigm.

Immuno-Oncology Approaches

While cancers can be classified in broad categories, tumors are specific to the patient. Our immuno-oncology approach uses the tumor’s specific and individual composition against itself by injecting the therapy directly into the tumor to stimulate an immune attack that spreads throughout the body to attack uninjected tumors.